COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Homeopathy for Post-operative (C. Section) Recovery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00725569
Recruitment Status : Completed
First Posted : July 30, 2008
Last Update Posted : October 20, 2009
Information provided by:
Shaare Zedek Medical Center

Brief Summary:

The planned study will be conducted in a prospective, randomized, double blind placebo controlled manner. Two "anti-traumatic" Homeopathic remedies (Arnica montana and Staphysagria) will be used. The selection of these remedies was based on a previous trial that showed a statistical difference in Hemoglobin levels favoring pregnant women treated with these drugs following delivery.

The proposed study will focus on the post-operative recovery of women undergoing Cesarean section. According to Homeopathic principles, these two remedies are believed to improve the "vital force", and will therefore improve convalescence following surgery in the study group. The study will include 90 women between the ages of 18 and 50 years who are scheduled for elective Cesarean Section. Exclusion criteria are: obesity (above 100kg), malignancy, psychiatric illness, diabetes and multipara pregnancies. Participants will be inducted following a detailed explanation by an MD and signing of an informed consent form, and then subdivided randomly into three groups numbering 30 in each: Two groups will be treated with homeopathic drugs of varied doses, and the third will get a placebo remedy which is indistinguishable from the other drugs. Outcome measures will include: 1. Blood loss - as estimated by a reduction in serum Hemoglobin levels. 2. Pain -to be evaluated by a numerical rating score (NRS) 3. Analgesic use 4. Length of post-operative stay and complications. 5. Quality of life outcomes - to be assessed using the MOS SF-36 questionnaire at one and four weeks following surgery. Although not expected, adverse events will be monitored.

If, as we anticipate, the homeopathic treatment proves to be both safe and effective in shortening the duration of post-operative healing, this will have significant implications, with respect to both healthcare costs and patient suffering. It will also open the door for further research in the field of trauma medicine, as well as other stress-related illness.

Condition or disease Intervention/treatment Phase
Cesarean Section Drug: Bellis perennis and Staphysagria (C6) Drug: Bellis perennis and Staphysagria (C30) Drug: Placebo Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Homeopathic Drugs Bellis Perennis ו- Staphysagria on the Post-operative Recovery, of Women Undergoing Cesarean Section- (an Exploratory) Double Blind, Placebo Controlled Study
Study Start Date : August 2008
Actual Primary Completion Date : April 2009
Actual Study Completion Date : April 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cesarean Section

Arm Intervention/treatment
Active Comparator: A
Bellis perennis and Staphysagria (C6)
Drug: Bellis perennis and Staphysagria (C6)
homeopathic remedy

Active Comparator: B
Bellis perennis and Staphysagria (C30)
Drug: Bellis perennis and Staphysagria (C30)
Homeopathic Remedy

Placebo Comparator: C
Placebo Remedy
Drug: Placebo
Placebo remedy, identical in size, shape and taste to treatment remedies

Primary Outcome Measures :
  1. pain, to be evaluated using a numerical rating score (NRS) on a 100mm scale (0= no pain whatsoever, 100 = unbearable pain). [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Analgesic Use [ Time Frame: 4 weeks ]
  2. Duration of Hospital Stay [ Time Frame: 4 weeks ]
  3. Time from Surgery to First Bowel Movement [ Time Frame: 4 days ]
  4. Blood Loss [ Time Frame: 4 days ]
  5. Post-operative Complications the following complications will be noted: Nausea, vomiting, abdominal distension, fever, urinary tract infection, thrombophlebitis, wound infection, wound hematoma, ileus, vaginal bleeding. [ Time Frame: 4 weeks ]
  6. Quality of Life Assessment [ Time Frame: 4 weeks ]
  7. Adverse Effects of Treatment [ Time Frame: 4 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • women hospitalized for elective C. Section, from the 1st to 3rd pregnancies.
  • Age < 50 years
  • Body weight < 100 kg
  • Signing of informed consent form

Exclusion Criteria:

  1. suspected/proven malignancy
  2. underlying Axis-1 psychiatric illness
  3. age < 18 years
  4. diabetes mellitus (NIDDM/IDDM)
  5. unable to comply with study proceedings

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00725569

Layout table for location information
Shaare Zedek Medical Center
Jerusalem, Israel, 91031
Sponsors and Collaborators
Shaare Zedek Medical Center
Layout table for investigator information
Principal Investigator: Menachem Oberbaum, M.D. Shaare Zedek Medical Center, Jerusalem, Israel
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dr. Menachem Oberbaum, Shaare Zedek Medical Center Identifier: NCT00725569    
Other Study ID Numbers: POR2008
First Posted: July 30, 2008    Key Record Dates
Last Update Posted: October 20, 2009
Last Verified: October 2008
Keywords provided by Shaare Zedek Medical Center:
Caesarian Section